01481nam 2200397 a 450 991069345850332120100922105331.0(CKB)3460000000108872(OCoLC)316525251(EXLCZ)99346000000010887220090320d2009 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierFDA's role in the evaluation of Avandia's safety[electronic resource] hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, June 6, 2007Washington :U.S. G.P.O.,2009.iii, 138 pages digital, PDF fileTitle from title screen (viewed on Mar. 20, 2009).Paper version available for sale by the Supt. of Docs., U.S. G.P.O."Serial no. 110-76."Includes bibliographical references (page 23).FDA's role in the evaluation of Avandia's safety RosiglitazoneSide effectsDiabetesChemotherapyDrugsUnited StatesTestingRosiglitazoneSide effects.DiabetesChemotherapy.DrugsTesting.GPOGPOBOOK9910693458503321FDA's role in the evaluation of Avandia's safety3476638UNINA